CLBS Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: The Motley Fool

Lisata (LSTA) Q3 2025 Earnings Call Transcript

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

3 years ago - By: Benzinga - Mentions: SST MEGL ATXI APP ...

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday

3 years ago - By: Benzinga - Mentions: BLRX ALT FUSN RYTM ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

3 years ago - By: InvestorPlace - Mentions: NBEV BIAF AMPE PXMD ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

3 years ago - By: Kahn Swick & Foti, LLC

CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at the BIO International Convention 2022

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

3 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference

4 years ago - By: Kahn Swick & Foti, LLC

CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

4 years ago - By: Caladrius Biosciences, Inc.

Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

4 years ago - By: Caladrius Biosciences, Inc.

CALADRIUS BIOSCIENCES INC (CLBS) Stock News

CLBS Latest News, Press Relases and Analysis

Lisata (LSTA) Q3 2025 Earnings Call Transcript

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday

12 Health Care Stocks Moving In Wednesday's Intraday Session

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group

Caladrius Biosciences to Present at the BIO International Convention 2022

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference

CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS

Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time